Sajikumar Sreedharan, Navakkode Sheeja, Sacktor Todd Charlton, Frey Julietta Uta
Department of Neurophysiology, Leibniz Institute for Neurobiology, D-39118 Magdeburg, Germany.
J Neurosci. 2005 Jun 15;25(24):5750-6. doi: 10.1523/JNEUROSCI.1104-05.2005.
Protein kinase Mzeta (PKMzeta) is a persistently active protein kinase C isoform that is synthesized during long-term potentiation (LTP) and is critical for maintaining LTP. According to "synaptic tagging," newly synthesized, functionally important plasticity-related proteins (PRPs) may prolong potentiation not only at strongly tetanized pathways, but also at independent, weakly tetanized pathways if synaptic tags are set. We therefore investigated whether PKMzeta is involved in tagging and contributes to a sustained potentiation by providing strong and weak tetanization to two independent pathways and then disrupting the function of the kinase by a selective myristoylated zeta-pseudosubstrate inhibitory peptide. We found that persistent PKMzeta activity maintains potentiated responses, not only of the strongly tetanized pathway, but also of the weakly tetanized pathway. In contrast, an independent, nontetanized pathway was unaffected by the inhibitor, indicating that the function of PKMzeta was specific to the tagged synapses. To further delineate the specificity of the function of PKMzeta in synaptic tagging, we examined synaptic "cross-tagging," in which late LTP in one input can transform early into late long-term depression (LTD) in a separate input or, alternatively, late LTD in one input can transform early into late LTP in a second input, provided that the tags of the weak inputs are set. Although the PKMzeta inhibitor reversed late LTP, it did not prevent the persistent depression at the weakly stimulated, cross-tagged LTD input. Conversely, although the agent did not reverse late LTD, it blocked the persistent potentiation of weakly tetanized, cross-tagged synapses. Thus, PKMzeta is the first LTP-specific PRP and is critical for the transformation of early into late LTP during both synaptic tagging and cross-tagging.
蛋白激酶Mζ(PKMzeta)是一种持续激活的蛋白激酶C亚型,在长时程增强(LTP)过程中合成,对维持LTP至关重要。根据“突触标记”理论,如果设置了突触标记,新合成的、功能重要的可塑性相关蛋白(PRP)不仅可以延长强强直刺激通路的突触增强,还可以延长独立的、弱强直刺激通路的突触增强。因此,我们通过对两条独立通路分别给予强强直刺激和弱强直刺激,然后用选择性肉豆蔻酰化ζ-假底物抑制肽破坏该激酶的功能,来研究PKMzeta是否参与标记过程并促进持续的突触增强。我们发现,持续的PKMzeta活性不仅维持了强强直刺激通路的增强反应,也维持了弱强直刺激通路的增强反应。相反,一条独立的、未强直刺激的通路不受抑制剂影响,这表明PKMzeta的功能对标记的突触具有特异性。为了进一步阐明PKMzeta在突触标记中的功能特异性,我们研究了突触“交叉标记”,即在一个输入中的晚期LTP可以在另一个独立输入中转化为早期晚期长时程抑制(LTD),或者相反,在一个输入中的晚期LTD可以在第二个输入中转化为早期晚期LTP,前提是弱输入的标记已设置。尽管PKMzeta抑制剂可逆转晚期LTP,但它并不能阻止弱刺激、交叉标记的LTD输入处的持续抑制。相反,尽管该药物不能逆转晚期LTD,但它阻断了弱强直刺激、交叉标记突触的持续增强。因此,PKMzeta是首个LTP特异性PRP,对突触标记和交叉标记过程中早期LTP向晚期LTP的转化至关重要。